Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
M-102.4 in Neurodegenerative Diseases: ACTRN12625000511437 Clinical Landscape Report 2026
18 September 2026
ACTRN12625000511437 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Usnoflast in Amyotrophic Lateral Sclerosis: NCT07023835 Clinical Landscape Report 2026
18 September 2026
NCT07023835 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imeroprubart in Myasthenia Gravis: NCT07039916 Clinical Landscape Report 2026
18 September 2026
NCT07039916 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Digoxin in Amyotrophic Lateral Sclerosis: NCT07047209 Clinical Landscape Report 2026
18 September 2026
NCT07047209 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GC-012F in Myasthenia Gravis: NCT07058298 Clinical Landscape Report 2026
18 September 2026
NCT07058298 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AD-64 in Metabolic Dysfunction Associated Steatohepatitis: CTRI/2025/07/090987 Clinical Landscape Report 2026
18 September 2026
CTRI/2025/07/090987 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context an…
9 min read
RAG-17 in Amyotrophic Lateral Sclerosis: NCT07077668 Clinical Landscape Report 2026
18 September 2026
NCT07077668 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RAG-21 in Amyotrophic Lateral Sclerosis: NCT07080801 Clinical Landscape Report 2026
18 September 2026
NCT07080801 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CB03 in Amyotrophic Lateral Sclerosis: NCT07082192 Clinical Landscape Report 2026
18 September 2026
NCT07082192 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AlloEx exosomes(The Foundation For Regenerative Medicine) in Motor Disorders: NCT07105371 Clinical Landscape Report 2026
18 September 2026
NCT07105371 clinical landscape for Motor Disorders: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Riluzole in Amyotrophic Lateral Sclerosis: NCT07093268 Clinical Landscape Report 2026
18 September 2026
NCT07093268 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
nL-TARD-001 in Amyotrophic Lateral Sclerosis: NCT07095712 Clinical Landscape Report 2026
18 September 2026
NCT07095712 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.